Slide 1: Oriola Corporation Interim report January-September 2021
Oriola Corporation Interim report January-September 2021
Slide 2: Q3 2021 key points
Q3 2021 key points Profitability improved and turnaround proceeding • Markets continued to recover in both Finland and Sweden. Market volume demand is close to 2019 levels • Invoicing and net sales increased 4.8% in constant currency • Adjusted EBIT increased to EUR 10.4 (6.3) million • Profitabilit
Slide 3: Q3: Invoicing +6.0% and net sales +6.1%
Q3: Invoicing +6.0 % and net sales +6.1% constant currency +4.8% and +4.8% Invoicing1 Net sales2 EUR million EUR million 2019 2020 2021 2019 2020 2021 +6% +6% 1 000 500 800 400 600 300 942 898 984 979 987 894 965 942 917 915 970 460 450 448 436 468 429 439 466 447 466 400 200 397 979 200 100 0 0 Q1
Slide 4: Adjusted EBIT increased to EUR 10.4 million
Adjusted EBIT increased to EUR 10.4 million – above 2020 and 2019 Adjusted EBIT Adjusted EBIT development1 EUR million EUR million 2019 2020 2021 10.4 0.1 10 10 9.1 2.1 8.0 8 8 6.9 0.7 1.1 6.3 6 5.6 6 10.4 3.7 4.1 4 4 6.3 2.1 2 2 0.3 0 0 -0.3 2020 Consumer Pharma Retail Group 2021 Q3 items Q3 Q1 Q2
Slide 5: Key figures YTD Q3
Key figures YTD Q3 continuing operations Invoicing Q1-Q3 Net sales Q1-Q3 Adjusted EBIT Q1-Q3 EUR million EUR million EUR million +4% +4% 3 000 2 897 1 400 1 383 2 778 1 335 50 2 754 1 275 2 589 2 465 1 200 1 132 1 157 970 439 466 40 917 915 429 844 1 000 370 33.0 2 000 823 378 29.5 30 800 9.4 898 98
Slide 6: Operating environment & Oriola
& Oriola Operating environment
Slide 7: Pharmacy market value and volume grew in Q3 in Sweden
Pharmacy market value and volume grew in Q3 in Sweden Pharmacy market value development in Sweden in Q3: +4.7% and +1.7%% in YTD Pharmacy volume grew in Sweden in Q3 Online pharmacy market size in Sweden Total online pharmacy market grew by 24% in Market shares in Q3 Pharmacy 397 market in Q3 BSEK 3
Slide 8: Pharmaceutical market value and volume grew in Q3
Pharmaceutical market value and volume grew in Q3 Volume increased Y/Y in Q3 and was close to the pre-pandemic levels Pharmaceutical market value development YTD: Finland +2.5% and Sweden +2.6% Finland Wholesale Sweden Wholesale Pharmaceutical Pharmaceutical market in value Q3: 2.8 BEUR 50 BSEK mark
Slide 9: Also Retail markets were growing in Q3
Also Retail markets were growing in Q3 Market share dose dispensing TG/OTC market value development +9.3% in Sweden in Q3 and +4.1% YTD Sweden Oriola’s market share of TG/OTC products Total Oriola 42% (43%) 245,000 Others 58% (57%) supply for pharmacies in Sweden in Q3 patients 24% (25%) from the to
Slide 10: Business Area reviews Q3 2021
Business Area reviews Q3 2021
Slide 11: Three customer-centric business areas
Three customer-centric business areas Consumer business area Pharma business area Retail business area Pharmacy services and products for Advanced logistics, expert and advisory A wide range of health and wellbeing consumer health and wellbeing in Sweden services for pharmaceutical companies, produc
Slide 12: Consumer Q3: Pharmacy market continued recovering, profitability improved
Consumer Q3: Pharmacy market continued recovering, profitability improved • Consumer activity and demand recovered Adjusted EBIT EUR million • Physical pharmacy market demand started to slowly recover 2019 2020 2021 towards the end of the Q3 6 5.4 • The net sales increased by 5.1% to EUR 200.2 milli
Slide 13: Pharma Q3: Increased profitability driven by market recovery
Pharma Q3: Increased profitability driven by market recovery Adjusted EBIT • Market demand recovering in both countries EUR million 2019 2020 2021 • Invoicing increased by 5.4% to EUR 745.0 6 5.2 million, (on a constant currency basis invoicing 5 4.7 increased by 4.4%) 4.1 4.2 4.1 • Net sales increa
Slide 14: Retail Q3: Improved market demand, increased profitability
Retail Q3: Improved market demand, increased profitability • Net sales increased by 6.6% to EUR 126.7 Adjusted EBIT EUR million million, (on a constant currency basis net sales 2019 2020 2021 increased by 5.1%), driven by 4 3.6 • Growth of patient volumes in dose dispensing • Increased demand for he
Slide 15: Profit for the period, EPS & Net Interest-Bearing Debt
Profit for the period, EPS & Net Interest - Bearing Debt Q3 2021
Slide 16: Q3: Profit for the period and EPS up 85% Y/Y
Q3: Profit for the period and EPS up 85% Y/Y Profit for the period Earnings per share EUR million EUR 2019 2020 2021 2019 2020 2021 8 0.08 6.8 6 0.06 5.1 4.5 4.1 4 3.7 0.04 0.04 0.03 0.02 2.0 0.02 0.02 2 1.7 0.02 0.9 0.01 0.01 0.01 0 0.00 -0.2 -0.00 -0.01 -0.01 -2 -1.6 -0.02 -1.7 Q1 Q2 Q3 Q4 Q1 Q2 Q
Slide 17: Q3: Operating cash flow declined, driven by change in working capital
Q3: Operating cash flow declined, driven by change in working capital Quarterly net cash flow from operating activities Q3 YTD 2021 change in cash EUR million EUR million 2019 2020 2021 80 200 70 60 -2.2 14.4 46 150 40 -94.3 28 27 20 13 100 9 4 168.2 0 -0 50 86.0 -20 -14 -16 -25 -40 0 Q1 Q2 Q3 Q4 Ca
Slide 18: Q3: Net Interest-Bearing Debt declined Y/Y
Q3: Net Interest-Bearing Debt declined Y/Y Net interest-bearing debt Net interest-bearing debt items EUR million EUR million 2019 2020 2021 200 Net interest-bearing debt item 30 Sep 2021 30 Sep 2020 Bank loans 65.5 126.5 (syndicated Bank & term) 150 Commercial papers 49.6 87.1 Advance payment from p
Slide 19: Oriola's short-term action plan
Oriola’s short-term action plan
Slide 20: Oriola's short-term action plan is to execute the turnaround and fix the foundation
Oriola’s short-term action plan is to execute the turnaround and fix the foundation Initiate Execute New business Complete effective successful strategy to be turnaround turnaround turnaround presented in & & & CMD implement new start fixing the continue rescheduled business foundation fixing the to
Slide 21: Short-term action plan to improve profitability during 2022
Short-term action plan to improve profitability during 2022 – impacts fully visible in 2023 1. Cost savings • Increased transparency and customer focus via the planned country-based structure. Simplified • Increased efficiency by optimizing footprint & streamlining country value streams. operating m
Slide 22: Q3 2021 Key take-aways
Q3 2021 Key take-aways Profitability improved – Turnaround proceeding Markets continued Invoicing and net Profitability Short-term New business to recover sales increased improved action plan for strategy – to be by 4.8% in turnaround; presented in CMD, constant currency first initiatives to resched
Slide 23: Outlook for 2021 unchanged
Outlook for 2021 unchanged The adjusted EBIT on a constant currency basis stays on the same level or increases from the 2020 level. The COVID-19 pandemic continues during 2021. Severity and duration of the pandemic remain unclear in Oriola’s operating environment. Oriola’s business outlook for 2021
Slide 24: Thank you!
Thank you! Our next events: 18/2/2022 Financial statements release 2021 IR contact: Katja Graff, Treasury & IR Manager, +358 10 429 013 or katja.graff@oriola.com